Mehmet Asim Bilen,MD
Assistant Professor at @EmoryUniversity, Genitourinary Oncologist at @WinshipAtEmory. Opinions=my own.
Last synced from Twitter 83d ago
Giants of Cancer Care | OncLive
To recognize and celebrate the individuals who have achieved landmark successes within the field of oncology.
The 27th Annual Scientific Retreat | Prostate Cancer Foundation
The Prostate Cancer Foundation Scientific Retreat is the foremost scientific conference in the world on the biology and treatment of prostate cancer.
#KCRCS20 | Welcome to the Kidney Cancer Research Summit by KidneyCAN
#KCRS20 is the 2nd annual Kidney Cancer Research Summit presented by KidneyCAN. #KCRS20 is a meeting focused on basic and translational science, as well as cutting edge translational research. The research presented at #KCRS20 is fueled by the...
Quantification of body composition in renal cell carcinoma patients: Comparing computed tomography and magnetic resonance imaging measurements - PubMed
Strong correlation of CT and MRI cross sectional measurements of skeletal muscle and adipose tissues supports the use of axial MRI images for comprehensive measurement of body composition. This has widespread implications for body composition...
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer | NEJM
Original Article from The New England Journal of Medicine — Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
Expertscape Publishes Top 10 Specialists in Lung Cancer - Cancer Therapy Advisor
Expertscape, a platform for discovering physicians excelling in the treatment and diagnosis of specific disease states, has released their rankings for US physicians who specialize in lung cancer.
Considerations for cancer immunotherapy biomarker research during COVID-19
"Considerations for cancer immunotherapy biomarker research during COVID-19" published on Sep 2020 by Bioscientifica Ltd.
Skeletal-Related Events in Patients with Metastatic Renal Cell Carcinoma: A Systematic Review - IOS Press
About one-third of advanced renal cell carcinoma (RCC) patients have bone metastases, which subsequently leads to the development of skeletal-related events (SREs), broadly defined to include surgery and radiation to bone, bone pain, pathological fra
2020 Scientific Retreat | Prostate Cancer Foundation
This years scientific retreat is a virtual event. Each attendee will need to register for the virtual meeting. If your colleague(s) would like to attend, they may visit pcf.org to register and receive a unique registration link. Register Here. A...
Title not found
Submit an Article
Instructions for Authors
Before submitting your article, please read the Instructions for Authors to understand the requirements for preparing and submitting a manuscript to the Journal. Please note that manuscripts...
Efficacy and Safety of Nivolumab Plus Ipilimumab versus Sunitinib in First-Line Treatment of Patients with Advanced Sarcomatoid Renal Cell Carcinoma
Purpose: Patients with advanced renal cell carcinoma with sarcomatoid features (sRCC) have poor prognoses and suboptimal outcomes with targeted therapy. This post hoc analysis of the phase III CheckMate 214 trial analyzed the efficacy of nivolumab...
IO Tox Management
The IO Tox Management app is developed to help physicians treating patients with Immunotherapy and/or Immunotherapy side effects. It provides recommended management of common toxicities related to immunotherapy. This management is based off of a...
District Days | KidneyCAN | Help from Home to Fund Cancer Research
This summer, KidneyCAN and local partners will be working from home to advocate for kidney cancer research funding. Join us! We need your voice.
Activity of cabozantinib after immune checkpoint blockade in metastatic clear-cell renal cell carcinoma
Cabozantinib is approved for the first and subsequent line treatment of metastatic
clear-cell renal cell carcinoma (ccRCC) based on trials in which most patients were
immune checkpoint blockade (ICB) naive. With an expanding role of ICB in earlier...
Considerations for cancer immunotherapy biomarker research during COVID-19 in: Endocrine-Related Cancer - Ahead of print
Mehmet Asim Bilen,MD
Check out our piece about biomarker research in the era of #COVID led by @JennyCarlisleMD @careyjans erc.bioscientifica.com/view/journals/… @HaydnKissick @WinshipAtEmory @emory_urology @EmoryUniversity @EmoryMedicine pic.twitter.com/SHn4Bwkr4L
222d